found Documents: 310

Announcements & Press Releases, Oncology / Immunology | 24 Nov 2021

HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy

2 items

— Follows important findings from the TATTON[1] study of the combination in EGFR inhibitor refractory lung cancer patients whose tumors harbor aberrations of MET — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, November 2

LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 8 Nov 2021

HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, November 8, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of HMPL-523 and HMPL-306 will be present

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 1 Nov 2021

HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma

2 items

— Follows multiple global studies of savolitinib in papillary renal cell carcinoma patients including SAVOIR and CALYPSO — — In CALYPSO, savolitinib and IMFINZI® combination demonstrated a 57% confirmed response rate in PRCC patients with

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 28 Oct 2021

HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China

2 items

Hong Kong, Shanghai & Florham Park, NJ –– Thursday, October 28, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase III trial in China of HMPL-523, a novel, investigational s

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

2021, Announcements & Press Releases, Oncology / Immunology | 29 Sep 2021

HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, September 29, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) announces that new and updated clinical data from several ongoing combination studies of surufatinib (

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

2021, Announcements & Press Releases, Group | 29 Sep 2021

HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture

2 items

Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, September 29, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, further to its announcement in March 2021 and following receipt of regulatory

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 21 Sep 2021

HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 21, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has initiated SURTORI-01, a Phase III study to evaluate the efficacy and safety

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 20 Sep 2021

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors

2 items

— Following surufatinib launch in China in January 2021; NDA acceptance by the U.S. FDA for review in June 2021; and MAA validation by the EMA in July 2021 all for advanced neuroendocrine tumors — Hong Kong, Shanghai & Florham Park,

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 Sep 2021

HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, September 13, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 8 Sep 2021

HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

2 items

— Follows important findings from the SAVANNAH study of this combination in lung cancer patients whose tumors harbor mutations or aberrations of EGFR and MET — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, September 8,

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 7 Sep 2021

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 7, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new analyses and updates on the ongoing studies of amdizalisib (PI3Kδ inhibitor HMP

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Group | 6 Sep 2021

HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, September 6, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Company’s ordinary shares, which trade on The Stock Exchange of Hong Kong Limit

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 26 Aug 2021

HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, August 26, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Group | 23 Aug 2021

HUTCHMED Selected as Constituent of Certain Hang Seng Indexes

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, August 23, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that HUTCHMED has been selected as a constituent stock of several indexes administered by Ha

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 9 Aug 2021

HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

2 items

- Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio - - Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milesto

LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)

Announcements & Press Releases, Group | 28 Jul 2021

HUTCHMED Reports 2021 Interim Results and Provides Business Updates

2 items

ELUNATE® in-market sales1 rose 186%, reflecting impact of in-house sales force Received 1st approval in China for ORPATHYS® and 2nd approval in China for SULANDA® U.S. and E.U. applications for surufatinib both accepted Raised $615m2 gross pr

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 28 Jul 2021

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer

2 items

— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR) in gastric cancer patients whose tumors harbor MET amplification — Hong Kong, Shanghai & Florham Park, NJ —

LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 16 Jul 2021

HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

2 items

– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for

HKEX - Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 Jul 2021

First Commercial Sale of ORPATHYS® in China Triggering a US$25 million Milestone Payment from AstraZeneca

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, July 13, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China of ORPATHYS® (savolitinib), HUTCHMED’s oral, potent, and high

HKEX - Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Group | 12 Jul 2021

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Monday, July 12, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX:13) today announces the full exercise of the over-allotment option of the Global Offering. Th

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 6 Jul 2021

HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with Advanced Solid Tumors in China

2 items

Hong Kong, Shanghai and Florham Park, NJ — Tuesday, July 6, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) has initiated a Phase I study of HMPL‑295, its investigative and highly selective oral inhibitor of ERK, which

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Group | 2 Jul 2021

HUTCHMED to Announce 2021 Half-Year Financial Results

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, July 2, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will be announcing its interim results for the six months ended June 30, 2021 on Wednesday, July 28, 2021 at 12:

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 1 Jul 2021

U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

2 items

– U.S. FDA has assigned a target action date of April 30, 2022 – – If approved, surufatinib would be HUTCHMED’s first novel oncology drug marketed outside of China – Hong Kong, Shanghai & Florham Park, NJ — Thursday,

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Group | 30 Jun 2021

HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, June 30, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the listing of its ordinary shares (“Shares”) on the Main Board of the Stoc

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Group | 23 Jun 2021

HUTCHMED Announces Pricing of Global Offering

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, June 23, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the pricing of its global offering (the “Global Offering”) of 104,000,000 n

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 22 Jun 2021

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

2 items

– First selective MET inhibitor approval in China in this setting – – First regulatory approval for the oral, potent and selective MET tyrosine kinase inhibitor – Hong Kong, Shanghai & Florham Park, NJ —Tuesday, June 22, 202

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 18 Jun 2021

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors

2 items

– Second New Drug Application (“NDA”) approved for Sulanda in China – – The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51% in patients with advanced pancreatic NET – Hong K

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 18 Jun 2021

HUTCHMED Launches Hong Kong Initial Public Offering

1 item

Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 18, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the launch of its Hong Kong public offering (the “Hong Kong Public Offering”),

View Announcement (PDF)

Announcements & Press Releases, Group | 20 May 2021

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program

1 item

– HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 8 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy and provide a corporate update – Hong Kong,

Download Press Release (PDF)

Announcements & Press Releases, Group | 17 May 2021

Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors

1 item

– HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to provide updates on recent progress and upcoming milestones – Hong Kong, Shanghai & Florham Park, NJ — Monday, May 17, 2021: HUTCHMED (China) Limited (“HUTCHME

Download Press Release (PDF)

Announcements & Press Releases, Group | 7 May 2021

HUTCHMED to Attend Upcoming Investor Conferences

1 item

Hong Kong, Shanghai & Florham Park, NJ — Friday, May 7, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of HUTCHMED, will participate in a virtual fireside chat a

Download Press Release (PDF)

Announcements & Press Releases, Group | 4 May 2021

Change of Company Name

1 item

Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, May 4, 2021: HUTCHMED (China) Limited (Nasdaq/AIM: HCM), formerly known as Hutchison China MediTech Limited, announces that, further to its “Results of Annual General Meeting” announcement

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 3 May 2021

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

1 item

– First NDA submission by HUTCHMED in the U.S.; product launch preparations underway – Hong Kong, Shanghai & Florham Park, NJ — Monday, May 3, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces th

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Apr 2021

HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China

1 item

— Single-arm study in ~180 patients, with ORR as primary endpoint — — Relapsed/refractory FL and MZL constitute approximately 25% of all NHL — — HMPL-689 trials are also underway in these and other NHL subtypes in the U.S., Europe an

Download Press Release (PDF)

Announcements & Press Releases, Group | 8 Apr 2021

HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Hong Kong, Shanghai & Florham Park, NJ — Thu

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Mar 2021

HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies

1 item

— HMPL-306 is the sixth innovative oncology drug candidate discovered in house by HUTCHMED to enter into global development — Hong Kong, Shanghai & Florham Park, NJ — Monday, March 29, 2021: Hutchison China MediTech Limited (“HUT

Download Press Release (PDF)

Announcements & Press Releases, Group | 26 Mar 2021

2020 Annual Report and Notice of Annual General Meeting

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Friday, March 26, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that its 2020 Annual Report together with the Notice of Annual General Meeting and the Form of Pr

View Announcement (PDF)

Announcements & Press Releases, Group | 24 Mar 2021

HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million

1 item

– Allows focus on China and global clinical development and market launches of key Oncology/Immunology assets – Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, March 24, 2021: Hutchison China MediTech Limited (“HUTCHME

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 24 Mar 2021

HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors

1 item

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 24, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated a Phase Ib/II study of surufatinib in combination with BeiGene’s tislelizumab in patients w

Download Press Release (PDF)

Group | 4 Mar 2021

Chi-Med becomes HUTCHMED

Today, we begin consolidating the two corporate identities that we have used since our inception. Hutchison China MediTech, or Chi-Med, has been used as our group identity, while Hutchison MediPharma has been the identity of our novel drug R&D

Announcements & Press Releases, Group | 4 Mar 2021

Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity

1 item

Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT Hong Kong, Shanghai & Florham Park, NJ––Thursday, March 4, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM), a

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 Jan 2021

Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Thursday, January 14, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presente

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 11 Jan 2021

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

1 item

Hong Kong, Shanghai, San Diego & Florham Park, NJ: Monday, January 11, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) today announce a strategic partnership to further dev

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Coverage | 30 Dec 2020

Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors

1 item

– Sulanda® is Chi-Med’s first oncology drug brought to market without a partnership and the company’s second oncology drug approved in China – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression o

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Dec 2020

Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

1 item

– Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acce

Download Press Release (PDF)

Announcements & Press Releases, Group, Press Coverage | 22 Dec 2020

Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, December 22, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 39th Annual JP Morgan Heal

Download Press Release (PDF)

Oncology / Immunology | 8 Dec 2020

Chi-Med Hosts Ground-breaking Ceremony for a Large-Scale Manufacturing Plant in Zhangjiang, Shanghai

1 item

Tuesday, December 8, 2020 Shanghai: Chi-Med (Nasdaq/AIM: HCM) today held a ground-breaking ceremony in Zhangjiang Hi-Tech Park, Shanghai, commencing construction of a large-scale manufacturing plant for innovative drugs. Representatives from the S

View Article (PDF)

Announcements & Press Releases, Group | 17 Nov 2020

Chi-Med Announces US$100 Million Equity Investment by CPP Investments

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 5 Nov 2020

Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Thursday, November 5, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of the first in human HMPL-689 Phase I dose escalation study will be pre

Download Press Release (PDF)

Announcements & Press Releases, Group | 30 Oct 2020

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Friday, October 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the

Download Press Release (PDF)

2 3 4 5 6 7